Vasculopathy in patients with Fabry disease: current controversies and research directions.
about
Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosisFabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Stroke and Fabry disease.Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Enzyme replacement therapy for Fabry disease: some answers but more questionsLimitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Cerebral hemodynamics and endothelial function in patients with Fabry diseaseFabry disease and early strokeInnate and Adaptive Immune Response in Fabry DiseaseLeft Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy.Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.Pharmacological small molecules for the treatment of lysosomal storage disorders.Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Treatment of lysosomal storage disorders: successes and challenges.Aetiological diagnosis of middle-aged and elderly cryptogenic ischaemic cerebral vascular disease.Hearing loss in children with Fabry disease.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Left ventricular hypertrophy or storage disease? the incremental value of speckle tracking strain bull's-eye.Angiotensin II impairs endothelial nitric-oxide synthase bioavailability under free cholesterol-enriched conditions via intracellular free cholesterol-rich membrane microdomains.Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease.Fabry disease; early diagnosis improves prognosis but diagnosis is often delayed.Initially Nondiagnosed Fabry's Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis.Functional transcranial Doppler: presymptomatic changes in Fabry disease.Basilar Artery Changes in Fabry Disease.Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.Fabry disease and Factor V Leiden: a potent vascular risk combination.Small-Vessel Vasculopathy Due to Aberrant Autophagy in LAMP-2 Deficiency.Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.Cerebral blood flow in patients with Fabry disease as measured by Doppler sonography is not different from that in healthy individuals and is unaffected by treatment.A pilot study of circulating microRNAs as potential biomarkers of Fabry disease.Immune-Mediated Myocarditis in Fabry Disease Cardiomyopathy
P2860
Q26745698-5F0D4698-E239-40C6-B3AA-0ED535A7F33CQ33645550-E9717A5E-4D12-47FC-9197-EECBB5BD6EE6Q33831482-2B8AF0DB-1656-4861-847B-85D351C7F432Q34061632-14C0A154-7AA3-4DB3-8A18-D52B68016534Q34257466-16BA923B-6CA1-4CBB-A1ED-69A9EAED2C25Q34703815-B3DAB89E-3685-4878-9775-34DBF47FD36FQ35009083-36E0731C-9D7B-4600-BA07-61729CB490E7Q35028532-25AFF2F0-1D3A-4FF0-AFE7-4500B5A22D27Q35037435-8306805F-E681-469C-8479-3A97FC75E2E7Q35110216-CC3E65FB-0866-41DF-959F-EE0BF09FD38BQ35800976-B82187B2-BF98-43D7-80C1-58B3A6A2E2CAQ36315348-879E87D7-0C94-46D1-855D-E7AC9261E54FQ36691965-EEE1D02F-0B6F-4DCC-9668-1FA0ED2D7242Q37799818-88D441CD-702E-4F99-BFEC-B050BBF99CE8Q37994740-693FD33D-515A-4FE0-977F-FCE810EAA75AQ38211269-5E801216-B062-430F-8AAF-18BE99E8473BQ38500772-C786688D-73A6-4F3E-8FC7-32938C8A5369Q38752239-35DC0134-4CA4-4813-89B0-7558D0130957Q38844401-D2DE13EA-A8A8-49BB-AE1A-10525486202DQ39186807-047E17FE-57EE-407F-AF78-4C7F155F0F4CQ40777016-0C10C967-312A-4873-AA50-3C7E21AEE637Q40940812-7374410F-88BF-4B68-A683-92B95869D1C3Q41905133-A5B102FA-31AD-43D8-90C0-D40381E55FC1Q42933875-97F3BC1F-E9B5-4369-A096-A5BECF078FB4Q46223558-8472756B-4F97-45FA-9037-1192366081ECQ47878415-DE40CE0C-055B-4796-8478-26578C901EE5Q48632125-30718AFE-3AF1-4959-831A-4F100E0FE924Q48664517-8A3462E1-3AAD-4C6A-A227-12F7A8809D3EQ49789477-8D043D8B-CC31-44E8-B79F-AF1B7D455BD8Q50353850-C7BCA04D-89FB-4CDD-BF6D-50BECB179177Q51357161-B93291C6-E30C-4861-A16D-EACB621A727FQ55361498-011BF3FF-8D36-40A2-9DAD-98661C9C89B0Q58127382-13457E99-9AB7-45BE-BD18-00A6339CA2C3
P2860
Vasculopathy in patients with Fabry disease: current controversies and research directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vasculopathy in patients with ...... rsies and research directions.
@en
Vasculopathy in patients with ...... rsies and research directions.
@nl
type
label
Vasculopathy in patients with ...... rsies and research directions.
@en
Vasculopathy in patients with ...... rsies and research directions.
@nl
prefLabel
Vasculopathy in patients with ...... rsies and research directions.
@en
Vasculopathy in patients with ...... rsies and research directions.
@nl
P2093
P1476
Vasculopathy in patients with ...... ersies and research directions
@en
P2093
C E M Hollak
F A Wijburg
G E Linthorst
S M Rombach
Th B Twickler
P304
P356
10.1016/J.YMGME.2009.10.004
P50
P577
2009-10-13T00:00:00Z